Navigation Links
Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
Date:2/2/2010

EXTON, Pa., Feb. 2 /PRNewswire-FirstCall/ -- Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications, announced today that David Pernock, Chairman of the Board of Directors, has been named Chief Executive Officer (CEO), effective immediately. Pernock most recently served as Senior Vice President (SVP), Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care and HIV at GlaxoSmithKline. He joined Fibrocell's Board of Directors last September.

"I'm pleased to take on the role of Fibrocell's CEO during this pivotal period for the company and our lead investigational cell therapy Laviv™ (azficel-T)(1)," said Pernock. "We are excited about the potential for this therapy as we continue to address the U.S. Food & Drug Administration's (FDA) requests as outlined in its complete response letter to our March 2009 biologics license application for Laviv's use in the treatment of moderate to severe nasolabial fold wrinkles."

Mr. Pernock takes on the role of Fibrocell Science's CEO with extensive leadership experience in healthcare sales and commercialization, building business units, partnerships, and brands at GlaxoSmithKline. During a long career at the multinational pharmaceutical company that culminated with his role as SVP, Mr. Pernock was promoted numerous times to levels of increasing responsibility including Vice President of Marketing, Pharmaceuticals; Vice President of Sales and Marketing, Oncology; Vice President of Managed Care; and, Vice President of Sales. Mr. Pernock holds a B.S. in Business Administration from Arizona State University. He is a director of Martek Biosciences Corporation and serves in many philanthropic organizati
'/>"/>

SOURCE Fibrocell Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for Wrinkles
2. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
3. Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.
4. California Life Science, Business, and Economic Development Experts Discuss Californias Bioscience Future
5. FRC: NIH Stem Cell Guidelines Reflect Poor Science, Ignore Real Hope for Patients
6. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
7. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
8. For creating new field of science, Texas chemist wins international prize
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research
11. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... DETROIT, Oct. 23 Caraco Pharmaceutical,Laboratories, Ltd. (Amex: ... and,first six months of Fiscal 2009 of $122.2 million ... $76.8 million, respectively,for the corresponding periods of Fiscal 2008. ... periods of Fiscal 2008. Pre-tax income,grew to $12.3 million ...
... MIAMI, Oct. 23 NOVIS Pharmaceuticals, Inc. today,announced ... been,appointed Chairman of the Board. The appointment was ... meeting and is effective immediately., (Logo: ... to take on this role at NOVIS, and ...
... Ltd (BioWisdom),the market leader in delivering healthcare ... release of OmniViz,Visualization Software for Patent Specialists., ... in competitive business and,technical intelligence analyses to ... can turn the analysis of thousands of,patents ...
Cached Biology Technology:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 7Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 8NOVIS Announces Appointment of John J. Arlotta as Chairman 2
(Date:4/17/2014)... study suggests that fish consumption advisories for expecting ... long-lived contaminants like persistent organic pollutants (POPs). ... researchers including University of Toronto Scarborough PhD student ... how different levels of environmental contamination, a mother,s ... in the body influenced exposure in her children. ...
(Date:4/17/2014)... release is available in German . ... to recognise objects; they also provide us with a continuous ... turn around, fall or sit still in a car ... trace on our retinas. Seemingly without effort, our brain calculates ... a stable position and a steady gaze during our own ...
(Date:4/17/2014)... The White House honored Clemson professor Rajendra Singh ... efforts to promote and expand solar deployment in ... the D. Houser Banks Professor of Electrical and ... Silicon Nanoelectronics, is considered a local hero leading ... and economic opportunity in solar power and driving ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... PARK, Maryland A University of Maryland-led team of ... the impacts of climate change could affect civil conflicts. ... between conflict, socio-economic conditions and climate. They will use ... The U.S. Department of Defense is funding the ...
... rid of excess energy through the production of hydrogen. Biologists at ... absence of oxygen. For this, they need the messenger molecule nitric ... blood cells of humans. With colleagues at the UC Los Angeles, ... Haemoglobin an old protein in a new look ...
... into the human genome more readily in tumors than ... from the University of Maryland School of Medicine,s Institute ... from the Human Genome Project, the 1,000 Genomes Project ... phenomenon of lateral gene transfer (LGT), the transmission of ...
Cached Biology News:DoD-funded research: Can climate change heat up conflict? 2When green algae run out of air 2Bacterial DNA may integrate into human genome more readily in tumor tissue 2
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... strain containing an overproducing clone of M-MLV ... catalyzes the polymerization of DNA using template ... of large mRNAs, >10 kb, may be ... lower RNase H activity than AMV Reverse ...
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
...
Biology Products: